Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
4573 South Broad St., Suite 150
Yardville, NJ 08620
A global non-profit advocacy organization, supporting patients, families and healthcare providers in the fields of MDS and its related diseases for over 30 years
© 2024 MDS Foundation. All rights reserved.
Latest News
Explore the forefront of MDS research, treatments, and community happenings to stay informed on the ever-evolving landscape of MDS care.
December 9, 2024
Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers
Taiho Oncology, Inc. presented findings from two studies at the 66th American Society of Hematology (ASH) Annual Meeting, focusing on oral therapies for myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN). The first study, a Phase 1 trial, evaluated ASTX030—a combination of azacitidine and cedazuridine—and established a recommended dose for Phase 2 trials, showing pharmacokinetic profiles comparable to subcutaneous azacitidine. The second study analyzed real-world data comparing INQOVI® (decitabine and cedazuridine) tablets with intravenous or subcutaneous hypomethylating agents, providing insights into clinical outcomes and treatment patterns. These studies underscore Taiho Oncology's commitment to developing oral hypomethylating agents that may reduce treatment burdens for patients with MDS and related conditions.
December 4, 2024
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
Keros Therapeutics has entered into an exclusive global license agreement with Takeda to develop and commercialize elritercept, a treatment for anemia and thrombocytopenia in patients with myelodysplastic syndrome (MDS) and myelofibrosis (MF).
Elritercept is currently in Phase 2 clinical trials for MDS and MF, with a Phase 3 trial for transfusion-dependent anemia in MDS patients set to begin enrollment soon. The partnership underscores Keros’ expertise in TGF-ß protein signaling and positions Takeda to expand its hematologic oncology portfolio.
November 12, 2024
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk
Syros Pharmaceuticals announced that its Phase 3 SELECT-MDS-1 trial, evaluating tamibarotene combined with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression, did not achieve its primary endpoint of complete response (CR) rate. The trial's intent-to-treat analysis showed a CR rate of 23.8% in the treatment arm versus 18.8% in the control arm, a difference that was not statistically significant (p = 0.2084). The combination therapy was generally well-tolerated, with an adverse event profile consistent with previous studies. As a result of these findings, Syros plans to discontinue the study, conduct a thorough review of the data, and assess future steps.
April 4, 2024
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals announced that their Phase 2 study of REZLIDHIA® (olutasidenib) in patients with mutant IDH1 acute myeloid leukemia (AML) who relapsed or were refractory to prior venetoclax-based regimens showed promising results. Olutasidenib achieved durable composite complete remission in 43.8% of patients, with a safety profile consistent with previous data. This suggests olutasidenib could be a valuable treatment for this challenging patient population.
January 23, 2024
Taiho Oncology announces publication of final results of the phase 3 ascertain clinical trial of oral decitabine and cedazuridine fixed dose combination (INQOVI®) in patients with MDS and CMML
Taiho Oncology announced the Phase 3 ASCERTAIN trial results, showing that oral INQOVI® (decitabine and cedazuridine) is pharmacologically equivalent to IV decitabine for treating MDS and CMML. The study reported a median overall survival of 32 months and a 62% overall response rate. Additionally, 20% of patients moved to transplantation. Safety findings were consistent with IV decitabine, with common adverse events like thrombocytopenia, neutropenia, and anemia. The oral formulation offers a convenient alternative to daily clinic visits for treatment.
December 6, 2023
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical
Syros Pharmaceuticals announced initial data from their SELECT-AML-1 Phase 2 trial showing a 100% complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) rate in newly diagnosed unfit AML patients with RARA gene overexpression treated with tamibarotene, venetoclax, and azacitidine, compared to 70% with venetoclax and azacitidine alone. The triplet regimen demonstrated favorable tolerability, with no new safety signals. Additional data from the trial is expected in 2024.
October 24, 2023
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Servier Pharmaceuticals announced that the FDA has approved TIBSOVO® (ivosidenib tablets) for the treatment of IDH1-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). TIBSOVO is the first targeted therapy approved for this subset of MDS patients. This approval is based on a Phase 1 study showing a 38.9% complete remission rate and an 83.3% overall response rate. This marks the fifth indication for TIBSOVO, reinforcing Servier’s leadership in mutant IDH inhibition.
September 12, 2023
The Myelodysplastic Syndromes Foundation and Sparkcures Join Forces To Enhance Clinical Trial Navigation for Myelodysplastic Syndromes Patients
The MDS Foundation partners with SparkCures to enhance clinical trial navigation for myelodysplastic syndromes (MDS) patients. SparkCures will develop a custom platform for personalized trial screening, aiming to simplify the complex landscape of trial options. The collaboration aims to empower patients, caregivers, and healthcare providers, with plans for international expansion in 2024.